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Introduction: Viral hepatitis is a worldwide, important health issue. The optimal
management of viral hepatitis infections faces numerous challenges. In this paper, we
describe how biobanking of biological samples derived from viral hepatitis patients
collected both in-hospital and during community outreach screenings provides a unique
collection of samples.
Materials and Methods: All samples and materials were provided with a study code
within the SLIMS system Study protocols and an informed consent form were approved
by the Antwerp University Hospital/University of Antwerp Ethical Committee. Systematic
biobanking was initiated in October 2014. Collected sample types include: (1) serum and
plasma of all newly diagnosed HBV, HCV, HDV, and HEV positive patients; (2) left-over
serum and plasma samples from all PCR analyses for HBV and HCV performed in the
context of routine clinical care; (3) left-over liver tissue not needed for routine histological
diagnosis after liver biopsy; and (4) additional virus-specific, appropriate sample types
using a scientific rationale-based approach. A community outreach screening program
was performed in three major Belgian cities. Serum, EDTA, Tempus Blood RNA and BD
Vacutainer CPT were collected. CPT tubes were centrifuged on-site and mononuclear
cells collected within 24 h.
Results: Concerning community screening: 298 individuals supplied all 4 sample types.
Samples were stored at −150◦C and were logged in the biobank SLIMS database.
Samples were used for HBV-related immunological and biomarker studies. DNA isolated
from plasma samples derived from chronic HBV patients was used to investigate
Single Nucleotide Polymorphism rs 1790008. Serum samples collected from chronic
hepatitis C patients were used to assess the efficacy of HCV treatment. Peripheral Blood
Mononuclear Cells (PBMC) isolated from chronic HBV patients and healthy controls were
used for different immunological study purposes. Virus isolated from biobanked stool of a
chronic hepatitis E patient was used to establish amousemodel for Hepatitis E infections,
allowing further HEV virology studies.
Conclusion: The establishment of a biobank with samples collected both in-hospital
and during community-outreach screening resulted in a unique, continuously expanding
collection of biological samples which provides an excellent platform for prompt answers
to clinically and translational relevant research questions.
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INTRODUCTION
Viral hepatitis is a worldwide, important health issue, mostly
caused by five different primary hepatotropic viruses: The
Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis
C virus (HCV), Hepatitis Delta Virus (HDV), and Hepatitis E
Virus (HEV). Infected patients are at increased risk of developing
liver-related events, including liver failure, liver cirrhosis and
hepatocellular carcinoma, ultimately culminating in liver-related
death (1–3). As such, viral hepatitis accounts for an estimated
1.45 million deaths annually, 90% of which are attributed to
chronic HBV and HCV infections (3). Importantly, this number
is on the rise, ranking viral hepatitis among the most important
causes of death worldwide (3).
HBV and HCV replicate non-cytopathically in human
hepatocytes. As such, liver damage caused by both viruses
incurs primarily through host immune responses (4–6). Chronic
infection develops in 10% of adult HBV and approximately
80% of HCV infected patients (4–6). The immunopathogenesis
of both infections is, however, not fully understood (1, 4–6).
As of now, HCV is curable, but HBV is not. The Hepatitis B
Virus forms a stable genomic “reservoir” within the nucleus
of infected hepatocytes. It integrates part of its genetic code
in the host genome and forms covalently closed circular DNA
(cccDNA), which acts as a mini-chromosome. Current standard
of care treatment suppresses viral replication, but fails to clear the
genomic “reservoir” (1). Additionally, HDV infections are seen
in up to 5% of chronic HBV patients, leading to more aggressive
liver disease, not seldom presenting with liver complications
before the fourth decade of life (7).
HEV infections are mostly self-limiting in immunocompetent
hosts, but chronic infections may develop in immunosuppressed
or HIV coinfected hosts. Little is known on its pathogenesis (8).
Management of chronic infections involves lowering the dosage
of immunosuppressants with addition of ribavirin treatment if
needed, which results in viral clearance in up to 80% of the
infected patients (8).
Clearly, the optimal management of viral hepatitis infections
faces numerous challenges. In this paper, we describe how
biobanking of biological samples derived from viral hepatitis
patients and healthy controls collected both in-hospital and
during community outreach screenings provides a unique
collection of samples that can be used to investigate unanswered
questions on the pathogenesis of viral hepatitis, and to
optimize management thereof. We report the quality metrics,
organization, output variables, the unique logistics, planning
and execution associated with biobanking for viral hepatitis
research. Subsequently, we show an overview of how biobanking
at the Antwerp University Hospital has resulted in novel insights
relating to viral hepatitis infections over the last 5 years.
METHODS
General Considerations
Funding from the CMI program (Center forMedical Innovation)
from the Flemish Government and existing biobanking
infrastructure for oncology (Tumorbank@UZA part of
the Belgian Virtual Tumorbank funded by the National
Cancer Plan) allowed for the establishment of storage
of biological samples for hepatotropic diseases, including
samples collected for the study of viral hepatitis. As such, the
established biobank is a disease-specific, hospital-integrated and
community-based biobank.
The biological samples are managed by trained biobank
personnel to ensure samples are handed, registered and stored
according to an established biobank quality management
system (QMS).
Important aspects of this QMS concerning sample
maintenance include:
• Processing of samples by dedicated biobank personnel via
Standard Operating Procedures (SOPs)
• Proper identification and traceability of samples via 2D
barcode labeling of samples encoded in a sample management
database (SLIMS, Genohm SA, Lausanne, Switzerland)
• Registration of important pre-analytical date/time stamps
such as collection, reception, centrifugation, fractionation and
storage in SLIMS
• Use of SPREC coding (9)
• Inclusion and exclusion criteria for uptake of samples in the
biobank via fixed decision trees
• Regular checks of the defined critical dataset in SLIMS
The protocol was carried out in accordance with the
recommendations of Good Clinical Practice, approved by
the Antwerp University Hospital/University of Antwerp
Ethical Committee (EC 15/21/227), with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
informed consent allows sampling and storage for blood,
urine, fecal and liver materials from hepatology outpatient and
inpatients clinics.
The established biobank comprises three different categories
of samples: (1) prospectively collected samples during in-
hospital based biobanking; (2) samples collected during outreach
community screenings; (3) left-over serum samples from
routine PCR analyses in the clinical laboratory and left-
over liver tissue samples not needed for routine histological
diagnosis at the department of pathology. Informed consent
was obtained from all patients from whom samples of
the first two categories were collected. For category 1,
informed consent was obtained during outpatient or inpatient
hospital care by attending medical staff. Presumed consent
was applicable to samples of category 3. Presumed consent
is based on Belgian law where it is stated that the use
of leftover human materials is allowed for diagnostic and
research purposes (19-12-2008, “Law pertaining the acquisition
and use of human materials for medical use in humans
or in scientific research”). These statues and reference to
the applicable law are written in the patient admission
information flyer.
Samples of category 1 and 2 are reserved for primary use
within a predefined timeframe by the investigators mentioned
in the ethical committee approval for biobanking. Upon
termination of the timeframe for primary use, these samples can
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be accessed by all researchers, including external researchers,
upon approval of both the Ethical Committee and Biobank
council. The concept of primary use does not apply to
samples of Category three. These samples can be accessed
immediately by all researchers upon ethical committee and
biobank council approval.
During outreach community screenings, individuals were
provided with Simplified Chinese and Traditional Chinese
informed consent forms and information brochures, and
additional translation support was provided on-site. These
forms were approved by the Ethical Committee as part of
the biobanking protocols. Prior to these community sessions,
Q&A sessions were held to communicate the objectives of
the study, the purpose of biobanking and the conditions of
confidentiality/traceability (coding) of results and samples.
Setting Up an In-Hospital Biobank for
Non-tumor Samples
Preparations for in-hospital biobanking consisted of the
integration of an extra option in the blood analysis request
forms, the creation of a workflow for the acquisition of informed
consents as well as regular exchanges between all parties involved
to discuss the optimal sample flow. Systematic biobanking was
subsequently initiated in October 2014. Collected sample types
include: (1) serum and plasma of all newly diagnosed HBV,
HCV, HDV, and HEV positive patients; (2) left-over serum and
plasma from all PCR analyses for HBV and HCV performed
in the context of routine clinical care; (3) left-over liver tissue
not needed for routine histological diagnosis after liver biopsy
and (4) additional virus-specific, appropriate biological sample
types using a scientific rationale-based approach. An overview of
the sample flow and collected sample types per virus is depicted
in Figure 1.
Biobanking of serum and plasma samples of newly diagnosed
patients is requested by the physician through the electronic
blood analysis request forms. Blood is then sampled by the
nursing staff and sent to the central biobank for centrifugation,
aliquotation and storage through an in-house pneumatic tube
system. Collaboration with the clinical laboratory allowed for
the collection of left-over serum and plasma samples of all
HBV and HCV PCR analyses performed for routine clinical
care purposes. Samples are temporarily stored at −20◦C at
the clinical laboratory and then transferred in batch to the
central biobank.
Hepatitis viruses all infect human hepatocytes. Unraveling
what happens at the site of infection, namely the liver, is
of utmost importance to understand the complex interplay
between virus and host. Left-over tissue not needed for
routine clinical histological evaluation provides a highly valuable
resource of samples in this regard. We therefore set up
a routine flow to collect and store left-over material in a
standardized way.
A thorough understanding of the immune responses against
hepatitis viruses requires a close collaboration between clinicians,
laboratory personnel and biobank. We optimized a workflow
for both intrahepatic as peripheral lymphocyte flowcytometric
analyses. In select cases a part of the left-over liver tissue
not needed for routine histological diagnosis is put in cell
culture medium. The latter is then transferred to the University
Laboratory for isolation of intrahepatic lymphocytes using a
Fluorescence Activation Cell Sorting (FACS) based approach.
Isolated intrahepatic lymphocytes are stored at −150◦C in the
central biobank. In addition, peripheral blood mononuclear
cells (PBMC) are collected. Sampling of heparinized blood is
requested by scientific staff through the electronic blood analysis
forms. Blood is taken by nursing staff and transferred to the
University Laboratory for isolation of PBMC by Ficoll-Hypaque
density centrifugation. Isolated samples are temporarily stored at
−80◦C at the Antwerp University laboratory before transfer to
−150◦C freezers at the central biobank. Temperature monitoring
is part of a hospital-wide system.
When compared to HBV and HCV, a unique aspect of
HEV infection is the fecal-oral transmission route, especially for
genotype 1 infections. The virus is readily detectable in human
stool and monitoring of viremia in stool has proven to be an
important tool in the management of chronic HEV infections
(8). To further characterize different aspects of Hepatitis E
infections, collection and biobanking of a wide range of body
fluids, including saliva, stool and urine in addition to blood
samples, was initiated. Left-over samples of stool not needed for
routine clinical monitoring of HEV viremia, are stored at−80◦C.
In addition, also PBMC, urine and saliva are collected through
nursing staff.
Biobanking During Outreach Screening
Projects
Asians have a higher seroprevalence of HBV infection, and
presumably of HCV infection as well (10–12). This population
is known to be difficult to reach, and epidemiological data in
the Belgian-Asian/Chinese migrant population is lacking. While
many screening studies have been performed in diaspora settings,
biobanking has not. Biobanking during outreach community
screening would constitute a unique “control” group: apart
from disease-specific information in Hepatitis B surface Antigen
(HBsAg) positive Asians, HBsAg negative persons in the same
target population would provide an excellent control group with
similar socio-demographic characteristics. These individuals
have a high chance to be exposed to HBV but would not
have been aﬄicted with HBV. This control group is typically
lacking in previous biobanking efforts, where they are recruited
from hospital or research environments, but not from the same
community with high HBV prevalence.
Preparations for the community screenings and biobanking
were executed simultaneously. This required a coordinated effort
from screening staff (administrative, paramedic and medical),
research laboratory staff, the hospital laboratory and the biobank
itself. Additionally, community leaders and volunteers were
crucial in providing preparatory, logistical and linguistic support
during screening and biobanking. Figure 2 provides an overview
of the activities performed by these different entities. Central
SLIMS labeling, as previously mentioned, was provided. To
facilitate the logistics of biobanking, standardized sachets with
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FIGURE 1 | Sample flow and types of samples collected during hospital-based biobanking.
FIGURE 2 | Sample flow and roles in community screening and biobanking.
all required materials for screening and biobanking (including
informed consent and request forms) were provided and labeled
using the code registered in SLIMS.
Screenings were organized in three major Belgian cities:
Antwerp, Brussels and Leuven between 9 a.m. and 5 p.m.
Serum, EDTA, Tempus Blood RNA (Applied Biosystems
Tempus Blood RNA tube, 3mL) and, for screenings organized
in Antwerp, BD Vacutainer CPT (Mononuclear Cell Preparation
Tubes, 4mL) were collected during screening events. CPT tubes
were centrifuged on-site for 15min at 1,500 relative centrifugal
force. CPT tubes were transported two or three times each
session (depending on amount of samples and time) to allow
for the University laboratory to perform the procedure to extract
peripheral blood mononuclear cells (PBMCs) in a timely manner
and prevent loss of cells by cell death. Serum, EDTA and Tempus
were temporarily stored on-site at +4◦C (cooling elements)
and after the end of each session, in the clinical laboratory, at
−20◦C. Within 2 days, serum, EDTA, Tempus and PBMCs were
subsequently stored in the biobank at −150◦C. Additionally,
plasma left-overs from CPT tubes were also stored.
Venepuncture testing for HBsAg, anti-HBc and anti-
HCV was performed at the Antwerp University Hospital
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TABLE 1a | Hospital-based sampling (informed consent).
2015 2016 2017 2018
Sample type Stored Retrieved Stored Retrieved Stored Retrieved Stored Retrieved
Serum 110 0 875 23 1,552 8 1,280 1
EDTA plasma 53 0 561 1 900 0 542 0
EDTA buffy coat non-viable 18 0 216 0 370 0 221 0
EDTA red blood cell 16 0 220 0 365 0 0 0
PBMC 0 0 62 0 139 13 80 12
Stool 0 0 2 1 5 0 7 0
Saliva 0 0 0 0 0 0 40 0
Urine 0 0 0 0 0 0 2 0
Intrahepatic lymphocytes 0 0 0 0 0 0 42 0
Total 197 0 1,936 25 3,331 21 2,214 13
Patients: 616
EDTA, Ethylenediaminetetraacetic acid tube; PBMC, peripheral blood mononuclear cells.
TABLE 1b | Hospital-based sampling (presumed consent/leftover samples).
pre-2014 2014 2015 2016 2017 2018
Sample type Stored Retrieved Stored Retrieved Stored Retrieved Stored Retrieved Stored Retrieved Stored Retrieved
Serum 151 0 287 0 785 0 105 6 183 0 480 0
Liver tissue 576 0 41 0 37 0 35 0 32 0 29 0
Total 727 0 328 0 822 0 140 6 215 0 509 0
Patients: 1,500
laboratory (Elecsys HBsAg II, anti-HBc, anti-HCV, Roche
Diagnostics GmbH, Mannheim, Germany). Additional funding
for community screening and biobanking was obtained from
grants (Roche Diagnostics, Gilead Life Sciences Inc., Bristol-
Myers Squibb, Sandoz).
RESULTS
Number of Collected Samples
The number of samples stored in and retrieved from the
biobank are shown in Tables 1, 2: samples obtained using
informed consent or using presumed consent (hospital based)
and community screening are shown. Biobanking from hospital
sources amounted to a total of 10,419 samples (2,116 patients),
community sourced samples to a total of 4,136 (462 persons).
Retrievals were used for study purposes, in accordance to
subsequent, Ethics Committee approved protocols. Forty-seven
non-conformities were logged from 2015 to 2018 (2, 7, 21
and 17 in 2015, 2016, 2017, and 2018, respectively). These
storage failures were due to erroneous sample withdrawal, pre-
storage Turn-Around Time (TAT) violation, insufficient data
collection/wrong identification, insufficient sample volume or
the incorrect use of sample recipients.
Cost Analysis
CMI structural funding for hepatotropic disease biobanking
amounted to e 98,560. Personnel, operational, storage, database,
TABLE 2 | Community-based sampling.
Stored Retrieved
Sample type Total Total At sampling 2015 2016 2017 2018
Serum, prime 421 421 0 0 0 0 0
Serum, aliquots 1,654 46 0 0 8 38 0
EDTA 159 0 0 0 0 0 0
Tempus 458 8 0 0 8 0 0
PBMC 217 19 0 0 8 11 0
CPT (plasma leftover) 299 238 0 238 0 0 0
Saliva 467 426 426 0 0 0 0
Dried blood spots 461 420 420 0 0 0 0
Total 4,136 1,578 846 238 24 49 0
Patients: 462
EDTA, Ethylenediaminetetraacetic acid tube; PBMC, peripheral blood mononuclear cells;
Tempus, RNA blood collection tube; CPT, Cell Preparation Tube (for PBMC sampling).
QC and administrative costs were covered using these funds.
Community sampling involved additional costs—these are
shown in Table 3.
DISCUSSION
Using a unique combination of outreach screening-based
and hospital-based biobanking we were able to establish a
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TABLE 3 | Community-based biobanking: costs (in euros).
Personnel Nursing staff 3, 634.0
Administrative assistant 1, 157.7
Language services 160.0
Study coordinator 1, 719.8
Physicians 4, 366.8
Total 11, 038.3
Logistics Blood tubes, venepuncture materials 4, 737.2
Event logistics (location rent, catering, etc.) 500.0
Communication costs 1, 211.0
Total 6, 448.2
Overall cost 17, 486.5
TABLE 4 | Staff and tasks involved in the preparation and execution of biobanking
during on-site screenings.
Task Preparatory/
support
On-site/
during
screening
Administrative staff Registration, on-site logistics 1 1
Paramedical staff Venepuncture 1 2-3
Study coordinator 1 1
Medical staff Informed consent, information 2 2
Volunteers Translation, community
coordination
4 5-10
Hospital laboratory Serological testing, temporary
storage
3 2
University laboratory PBMC isolation and
temporary storage
2 3-4
Biobank Database, labeling, storage,
sample processing and QA
3 1
continuously expanding collection of biological samples that
enables a prompt answer to several relevant clinical and
translational research questions in the field of viral hepatitis.
Numerous challenges arose during the execution of the
project. Both types of biobanking required a different approach
with inherently also different challenges. As for community
outreach screening-based biobanking, despite the uniformity
in data entry, labeling and storage, high personnel input
from all participating entities is necessary to ensure success
(Table 4). Additionally, a single coordinator is needed to ensure
continuity and to remedy and track logistical and quality
variance, for instance; traffic delayed CPT Heparine shipments
from the screening locations to the university laboratory.
This staff member had initially been planned to also perform
screening, but personnel redundancy was quickly activated
to ensure CPT Heparine transport could continue, whilst
also being able to continue screening activities. By design,
sample complexity was kept at a minimum, but the latter
issue illustrates that PBMC collection in particular proved
to be challenging during community outreach screening-
based biobanking.
FIGURE 3 | HBsAg quantification compared to duration of treatment induced
viral suppression (in months).
Community screenings typically scale from tens of samples
to hundreds or even thousands (13). In our experience,
±100 is an upper limit that our clinical and research
laboratories could handle for sample processing and testing
within turnaround times (TAT) that fall within performance
characteristics. Serum samples, e.g., which needed to be tested
for HBV and HCV serology, arrived in bulk. The platform
which was used (Roche Diagnostics Elecsys, Modular) was
not designed to rapidly run such a large number of samples.
Additionally, the samples arrived after the screening event
had ended, plus, some events were held on weekends. Thus,
staffing at the clinical laboratory was lower than during
weekdays. Despite these challenges, analytical TATs were within
5 days.
Hospital based biobanking presented different challenges
(14, 15). Staffing and logistics are less time and resource
intensive, as systems to obtain, process and store samples
are already in place on-site. However, samples from healthy
controls (including those who are not necessarily negative
for a specific disease) are not collected during hospital
based biobanking as opposed to screening/community settings.
Patient recruitment in a hospital setting is more specific, and
dedicated study coordinators need to monitor, often complex,
inclusion criteria.
Biobanked serum and plasma has so far been used for different
purposes; one of which was the quantification of Hepatitis B
surface Antigen levels in chronic hepatitis B patients. HBsAg
quantification (“qHBsAg”) provides extra information in terms
of the natural history of a person chronically infected with
HBV. In our center, we have observed that qHBsAg slowly
declines when patients are treated with nucleoside/nucleotide
analog antiviral therapy (Figure 3). Recent literature suggests
that qHBsAg levels may guide physicians in their decision to
interrupt long-term antiviral treatment for chronic hepatitis
B (10).
DNA isolated from plasma samples derived from chronic
HBV patients was used in an international multicentre study
to investigate the prevalence of a Toll-Like Receptor 7-specific
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FIGURE 4 | Representative FACS plot showing viability of lymphocytes in PBMC 3 years after collection.
Single Nucleotide Polymorphism (SNP) rs 1790008 in a large
group of chronic HBV infected patients (n = 1,054) and healthy
individuals (n = 231). The SNP was almost exclusively detected
in Caucasian subjects and was much more prevalent in healthy
Caucasian females when compared to HBV infected Caucasian
females, suggesting that the SNP might provide protection
against chronic HBV infection in this population (11). Serum
samples collected from chronic hepatitis C patients were used in
an international clinical trial to assess the efficacy of an 8-week
treatment regimen of ledipasvir/sofosbuvir in HCV genotype 4
infected patients. Among a total of 39 included patients, 6 (of
whom 2 were patients at the Antwerp University Hospital) did
not meet the primary study endpoint, being HCV RNA negative
at 12 weeks after therapy. Retrospective phylogenetic analyses on
biobanked samples revealed that 4/6 of these patients had been
reinfected (12).
PBMC isolated from chronic HBV patients and healthy
controls showed excellent viability 3 years after isolation
(Figure 4), allowing for use for different immunological study
purposes. In one study, paired serum and PBMC samples of
chronic Hepatitis B patients were used to study Hepatitis B
specific B cell responses. Results revealed a strong association of
a potent Hepatitis B-core specific B cell response with clinical
parameters in both treated and untreated patients (16). In
another study, the global B cell transcriptome was profiled in
chronic HBV infected patients and compared to healthy controls
using a systems biology approach. Peripheral B cells of chronic
HBV patients showed clinical phase dependent transcriptome
alterations and proved to be very different from intrahepatic B
cells on a transcriptome level (17).
Virus isolated from biobanked stool of a chronic hepatitis
E patient was successfully used to establish a mouse model
for Hepatitis E infections, allowing further HEV virology
studies (18, 19). Interestingly, using biobanked urine
samples, we discovered that HEV RNA can be detected in
urine samples.
Of final note, the higher amount of retrieved samples from
community biobanking is largely due to requirements in study
protocols. Going forward, biobank procedures have been put
in place to facilitate third-party use of samples. A biobank
committee (with principal investigators of studies that collected
samples in the biobank) will process and evaluate requests on
scientific merit, logistical feasibility and ethical considerations.
CONCLUSION
In conclusion, in this chapter we described how the establishment
of a biobank with samples collected both in-hospital and
during community-outreach screening, resulted in a unique,
continuously expanding collection of biological samples which
provides an excellent platform for prompt answers to clinically
and translationally relevant research questions. This information
may guide other centers in setting up similar projects in possibly
different contexts.
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